425 related articles for article (PubMed ID: 12959218)
1. Aberrated levels of cerebrospinal fluid chemokines in Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.
Press R; Pashenkov M; Jin JP; Link H
J Clin Immunol; 2003 Jul; 23(4):259-67. PubMed ID: 12959218
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells in the cerebrospinal fluid and peripheral nerves in Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.
Press R; Nennesmo I; Kouwenhoven M; Huang YM; Link H; Pashenkov M
J Neuroimmunol; 2005 Feb; 159(1-2):165-76. PubMed ID: 15652416
[TBL] [Abstract][Full Text] [Related]
3. Altered cerebrospinal fluid index of prealbumin, fibrinogen, and haptoglobin in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy.
Zhang HL; Zhang XM; Mao XJ; Deng H; Li HF; Press R; Fredrikson S; Zhu J
Acta Neurol Scand; 2012 Feb; 125(2):129-35. PubMed ID: 21434877
[TBL] [Abstract][Full Text] [Related]
4. Expression of chemokines in cerebrospinal fluid and serum of patients with chronic inflammatory demyelinating polyneuropathy.
Mahad DJ; Howell SJ; Woodroofe MN
J Neurol Neurosurg Psychiatry; 2002 Sep; 73(3):320-3. PubMed ID: 12185171
[TBL] [Abstract][Full Text] [Related]
5. The expression pattern of inflammatory mediators in cerebrospinal fluid differentiates Guillain-Barré syndrome from chronic inflammatory demyelinating polyneuropathy.
Sainaghi PP; Collimedaglia L; Alciato F; Leone MA; Naldi P; Molinari R; Monaco F; Avanzi GC
Cytokine; 2010 Aug; 51(2):138-43. PubMed ID: 20538476
[TBL] [Abstract][Full Text] [Related]
6. Immune Cell Profiling of the Cerebrospinal Fluid Provides Pathogenetic Insights Into Inflammatory Neuropathies.
Heming M; Schulte-Mecklenbeck A; Brix T; Wolbert J; Ruland T; Klotz L; Meuth SG; Gross CC; Wiendl H; Meyer Zu Hörste G
Front Immunol; 2019; 10():515. PubMed ID: 30984164
[No Abstract] [Full Text] [Related]
7. Validation of elevated levels of interleukin-8 in the cerebrospinal fluid, and discovery of new biomarkers in patients with GBS and CIDP using a proximity extension assay.
Kmezic I; Gustafsson R; Fink K; Svenningsson A; Samuelsson K; Ingre C; Olsson T; Hansson M; Kockum I; Adzemovic MZ; Press R
Front Immunol; 2023; 14():1241199. PubMed ID: 38077366
[TBL] [Abstract][Full Text] [Related]
8. T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.
Csurhes PA; Sullivan AA; Green K; Pender MP; McCombe PA
J Neurol Neurosurg Psychiatry; 2005 Oct; 76(10):1431-9. PubMed ID: 16170091
[TBL] [Abstract][Full Text] [Related]
9. [Immunopathology and treatments of Guillain-Barré syndrome and of chronic inflammatory demyelinating polyneuropathy].
Radziwill AJ; Kuntzer T; Steck AJ
Rev Neurol (Paris); 2002 Mar; 158(3):301-10. PubMed ID: 11976589
[TBL] [Abstract][Full Text] [Related]
10. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study.
Ruts L; Drenthen J; Jacobs BC; van Doorn PA;
Neurology; 2010 May; 74(21):1680-6. PubMed ID: 20427754
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of production of MIP-1alpha, MCP-1 and MIP-2 and potential role of neutralization of these chemokines in the regulation of immune responses during experimental autoimmune neuritis in Lewis rats.
Zou LP; Pelidou SH; Abbas N; Deretzi G; Mix E; Schaltzbeerg M; Winblad B; Zhu J
J Neuroimmunol; 1999 Aug; 98(2):168-75. PubMed ID: 10430050
[TBL] [Abstract][Full Text] [Related]
12. Oligoclonal IgG bands in chronic inflammatory polyradiculoneuropathies.
Ruiz M; Puthenparampil M; Campagnolo M; Castellani F; Salvalaggio A; Ruggero S; Toffanin E; Cacciavillani M; Gallo P; Franciotta D; Briani C
J Neurol Neurosurg Psychiatry; 2021 Sep; 92(9):969-974. PubMed ID: 33850000
[TBL] [Abstract][Full Text] [Related]
13. CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS.
Capodivento G; De Michelis C; Carpo M; Fancellu R; Schirinzi E; Severi D; Visigalli D; Franciotta D; Manganelli F; Siciliano G; Beronio A; Capello E; Lanteri P; Nobile-Orazio E; Schenone A; Benedetti L; Nobbio L
J Neurol Neurosurg Psychiatry; 2021 Mar; 92(3):303-310. PubMed ID: 33093191
[TBL] [Abstract][Full Text] [Related]
14. Intrathecal cytokine profile in neuropathy with anti-neurofascin 155 antibody.
Ogata H; Zhang X; Yamasaki R; Fujii T; Machida A; Morimoto N; Kaida K; Masuda T; Ando Y; Kuwahara M; Kusunoki S; Nakamura Y; Matsushita T; Isobe N; Kira JI
Ann Clin Transl Neurol; 2019 Nov; 6(11):2304-2316. PubMed ID: 31657126
[TBL] [Abstract][Full Text] [Related]
15. Monocyte chemoattractant protein 1 and chemokine receptor CCR2 productions in Guillain-Barré syndrome and experimental autoimmune neuritis.
Orlikowski D; Chazaud B; Plonquet A; Poron F; Sharshar T; Maison P; Raphaël JC; Gherardi RK; Créange A
J Neuroimmunol; 2003 Jan; 134(1-2):118-27. PubMed ID: 12507779
[TBL] [Abstract][Full Text] [Related]
16. IL-8 as a potential biomarker in Guillain-Barre Syndrome.
Breville G; Lascano AM; Roux-Lombard P; Lalive PH
Eur Cytokine Netw; 2019 Dec; 30(4):130-134. PubMed ID: 32096474
[TBL] [Abstract][Full Text] [Related]
17. Antibodies to LM1 and LM1-containing ganglioside complexes in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy.
Kuwahara M; Suzuki S; Takada K; Kusunoki S
J Neuroimmunol; 2011 Oct; 239(1-2):87-90. PubMed ID: 21914557
[TBL] [Abstract][Full Text] [Related]
18. Sequential expression of chemokines in experimental autoimmune neuritis.
Kieseier BC; Krivacic K; Jung S; Pischel H; Toyka KV; Ransohoff RM; Hartung HP
J Neuroimmunol; 2000 Oct; 110(1-2):121-9. PubMed ID: 11024541
[TBL] [Abstract][Full Text] [Related]
19. Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10.
Kieseier BC; Tani M; Mahad D; Oka N; Ho T; Woodroofe N; Griffin JW; Toyka KV; Ransohoff RM; Hartung HP
Brain; 2002 Apr; 125(Pt 4):823-34. PubMed ID: 11912115
[TBL] [Abstract][Full Text] [Related]
20. Antibody responses to peptides of peripheral nerve myelin proteins P0 and P2 in patients with inflammatory demyelinating neuropathy.
Inglis HR; Csurhes PA; McCombe PA
J Neurol Neurosurg Psychiatry; 2007 Apr; 78(4):419-22. PubMed ID: 17158557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
